Recent news on Imatinib Mesylate

International Approvals: Focetria, Zetia, Gleevec  -  May 14, 2007
Medscape (subscription)On March 8, Health Canada approved 2 new indications for imatinib mesylate (Gleevec tablets, Novartis Pharmaceuticals Canada, Inc), allowing its use as a

Pfizer Launches New Cancer Treatment In NZ  -  May 3, 2007
Scoop.co.nz,...cell carcinoma (RCC) and gastrointestinal stromal tumour (GIST), after the failure of imatinib mesylate treatment due to resistance or intolerance.

Gleevec Decreases Cancer Recurrence for Patients with Primary ...  -  Apr 13, 2007
PressZoom (press release),...a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec ®) after complete removal

Positive Results Prompt US National Cancer Institute to Make ...  -  Apr 12, 2007
PR Newswire (press release),About Gleevec Gleevec(R) (imatinib mesylate) is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant

Novartis case: arguments end  -  Mar 28, 2007
Hindu,...commenced hearing on the statutory appeal of the company against the rejection of its application to patent beta crystalline form of imatinib mesylate,

Novartis case: HC hears appeal  -  Mar 28, 2007
Chennai Online,...filed by the firm challenging rejection of its application for patenting beta crystalline form of Imatinib Mesylate under Section 3(d) of the Act.

Govt defends stance in Novartis patent suit  -  Mar 27, 2007
Daily News & Analysis,...against the rejection of its patent application for beta crystalline form of imatinib mesylate and also challenging section 3 (d) of the Patents Act,

INNOVIVE Pharmaceuticals Announces Interim Phase I Data on INNO ...  -  Apr 16, 2007
Genetic Engineering News (press release),1, 2005), INNO-406 is 25 to 55 times more potent than imatinib in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth

Health Canada approves SPRYCEL(TM), a new treatment for chronic ...  -  Mar 28, 2007
CNW Telbec (Communiqués de presse),...of adults with chronic, accelerated or blast phase CML who fail or are intolerant to prior therapy including imatinib mesylate (marketed as Gleevec(R)).

Gleevec available to patients in post-surgical GIST study  -  Apr 15, 2007
News-Medical.net,Investigators will begin offering Gleevec (imatinib mesylate) tablets to patients receiving placebo in a major North American clinical trial after an

Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors  -  Apr 16, 2007
MedIndia,...placebo-controlled clinical trial for patients with primary GIST, showed that patients who received imatinib mesylate (Gleevec) after complete removal

Positive Results Prompt US National Cancer Institute to Make ...  -  Apr 12, 2007
PR Newswire (press release),Gleevec(R) (imatinib mesylate) is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant

Positive Results Prompt US National Cancer Institute to Make ...  -  Apr 12, 2007
Earthtimes.orgEAST HANOVER, NJ, April 12 -- Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North

PWRM: Files Utility Patent Application for Resistance Test w ...  -  Apr 10, 2007
Therapeutics Daily (subscription) (press release),The patent application covers a test, a drug target and therapeutic design specifications with the potential to overcome resistance to imatinib mesylate

The Fred Hutchinson Cancer Research Center Adopts the BioMark ...  -  Apr 19, 2007
Genetic Engineering News (press release),...single base pair mutations that develop in the ABl kinase domain in CML cells, which often cause resistance to imatinib mesylate (drug therapy).

OHSU Cancer Institute, 1 Of Largest In GIST Study And Gleevec  -  Apr 15, 2007
Medical News Today (press release),...placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST) showed that patients who received imatinib mesylate

Gleevec reduces recurrence in colon cancer  -  Apr 14, 2007
Cancerfacts.com,The pill, sold as Gleevec®(imatinib mesylate) in the US and as Glivec® outside the US, was first approved by the FDA in 2001 for treatment of chronic

Health Highlights: April 13, 2007  -  Apr 13, 2007
Atlanta Journal Constitution (subscription),People who took the drug Gleevec (imatinib mesylate) after having a particular type of gastrointestinal tumor removed were significantly less likely to have

Gleevac found to dramatically reduce cancer recurrence risk  -  Apr 13, 2007
DailyIndia.com,The efficacy of imatinib mesylate (Gleevec) in preventing a recurrence of gastrointestinal stromal tumour (GIST) was observed during a placebo-controlled

Gleevac found to dramatically reduce cancer recurrence risk  -  Apr 13, 2007
South Asian Women's Forum,The efficacy of imatinib mesylate (Gleevec) in preventing a recurrence of gastrointestinal stromal tumor (GIST) was observed during a placebo-controlled

National Cancer Institute to Make Gleevec® Available to Patients ...  -  Apr 12, 2007
EndoNurse,EAST HANOVER, NJ -- Investigators will begin offering Gleevec® (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical

Contract win with Novartis Canada  -  Apr 10, 2007
Laboratory Talk,These services involve Novartis's blood level monitoring programme for Gleevec (imatinib mesylate), a medication approved for the treatment of patients with

Warnex to Perform LC/MS and PCR Services for Pharmacogenetic Study ...  -  Apr 6, 2007
MassSpec.net (press release),These services involve Novartis' Blood Level Monitoring Program for Gleevec® (imatinib mesylate), a medication approved for the treatment of patients with

Warnex to perform pharmacogenetic and bioanalytical services for ...  -  Apr 5, 2007
CNW Telbec (Communiqués de presse),These services involve Novartis' Blood Level Monitoring Program for Gleevec(R) (imatinib mesylate), a medication approved for the treatment of patients with

Novartis plea shifted to appellate board  -  Apr 5, 2007
Chennai Online,...by Novartis to challenge the rejection of its application for patenting beta crystalline form of "imatinib mesylate" under Section 3(d) of the Act.

Wockhardt moves HC for patent law  -  Apr 3, 2007
Economic Times,...came a few months after it rejected Novartis’ patent application for anti-cancer drug Glivec (known by its generic name, imatinib mesylate).

ChemGenex Announces Initiation of Second Phase 2/3 Clinical Trial ...  -  Apr 3, 2007
Genetic Engineering News (press release),CML patients routinely receive treatment with imatinib mesylate (Gleevec(R)) and dasatinib (Sprycel(R)), TKIs that are approved in both the United States

ChemGenex Announces Initiation of Second Phase 2/3 Clinical Trial ...  -  Apr 3, 2007
Business Wire (press release),CML patients routinely receive treatment with imatinib mesylate (Gleevec ® ) and dasatinib (Sprycel ® ), TKIs that are approved in both the United States

`Process of grant or rejection of patent is a quasi-judicial function'  -  Mar 27, 2007
Hindu,When a batch of petitions filed by Novartis against the refusal to patent its beta crystalline form of imatinib mesylate came up for hearing before a

Sutent Achieves First Line EAU Approval For Kidney Cancer  -  Mar 28, 2007
Medical News Today (press release),...and/or metastatic malignant gastrointestinal stromal tumors (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance.

Madras HC takes up lawsuit against denial of drug patent  -  Mar 27, 2007
DailyIndia.com,Glivec is the brand name under which Novartis sells 'imatinib mesylate' and generic drug manufacturers argue it is pricing that lies at the heart of the

Billion dollar babies—biotech drugs as blockbusters  -  Apr 3, 2007
Nature.com (subscription),Two targeted cancer therapies, Basel-based Novartis' Gleevec (imatinib mesylate), and Genentech's Herceptin (trastuzumab), are oft-cited examples of the

Pfizer's Sutent® Achieves First Line Recommendation For Treatment ...  -  27 Mar 2007
Medical News Today (press release),...and/or metastatic malignant gastrointestinal stromal tumors (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance.

Novartis: patents provision bereft of guidelines  -  27 Mar 2007
Hindu,The impugned order, turning down Novartis' patent application for beta crystalline form of imatinib mesylate, itself said the product had 30 per cent of

Madras HC to rule on Novartis’ patent case  -  Mar 5, 2007
Economic Times,However, Glivec (generic name: Imatinib mesylate) is not an incremental innovation and is not either a case of evergreening. “Glivec is a new drug,

Interruption of Treatment with Gleevec® Not Recommended for GIST  -  Mar 23, 2007
Cancer Consultants (press release),According to an article published in the Journal of Clinical Oncology, interruption in treatment with Gleevec® (imatinib mesylate) is not recommended for

Sutent achieves first line EAU approval for kidney cancer  -  Mar 22, 2007
SpiritIndia,...and/or metastatic malignantgastrointestinal stromal tumors (GIST) after failure of imatinib mesylate treatment due toresistance or intolerance.

Sutent achieves first line EAU approval for kidney cancer  -  Mar 22, 2007
HULIQ,...and/or metastatic malignant gastrointestinal stromal tumors (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance.

Dead Man Walking  -  Mar 9, 2007
Times of India,Chances are you have never heard of the drug, imatinib mesylate, let alone Section 3 (d) of India's Patent Amendment Act of 2005.

'Biomarkers will provide a dynamic approach'  -  Mar 8, 2007
Express Pharma,For exampletrastuzumab (Genentech's Herceptin), imatinib mesylate (Novartis's Gleevec), and cetuximab (ImClone's Erbitux). Besides Biocon, Dr Reddy's Labs

Novartis: court poses queries on core grounds of challenge  -  Mar 5, 2007
Hindu,The writ petitions are against the rejection of an application to patent Novartis' beta crystalline form of imatinib mesylate, by an order dated January 25,

Two-gene Test Correctly Distinguishes GIST from Leiomyosarcoma  -  Feb 28, 2007
Cancer Consultants (press release),...treatment for GIST typically includes surgical removal of as much cancer as possible and treatment with the targeted agent Gleevec® (imatinib mesylate).

Group Purchasing Organization Expands Ability to Participate in ...  -  Feb 28, 2007
Atlantic Information Services, Inc.,He says that cancer therapy Gleevec (imatinib mesylate) is a good example: "They stopped the trial early and put all the participants on the therapy"

Patent Act echo snares Novartis  -  Feb 23, 2007
Daily News & Analysis,Imatinib mesylate, the chemical name for Glivec, for which Novartis sought patent, is a derivative of Imatinib free base, and does not contain any new

Novartis' charges against Indian patent law refuted  -  Feb 22, 2007
Moneycontrol.com,...for beta crystalline form of imatinib mesylate, Mr Gopalan said that there was nothing in the provisions of the Act which could be said to be arbitrary.

'Patent Act amendment can't be queried'  -  Feb 24, 2007
Chennai Online,...giant Novartis AG, challenging rejection of its application for patenting beta crystalline form of Imatinib Mesylate under section 3(d) of the Act.

Clinical Data Supporting Development of ChemGenex’s Ceflatonin ...  -  Feb 14, 2007
Business Wire (press release),...patients who had failed treatment with Gleevec ® (imatinib mesylate) have been published in Cancer (the journal of the American Cancer Society).

Waxman, EU Parliamentarians join agitation against Novartis  -  Feb 14, 2007
Business Standard,It is also challenging a decision of the Indian patent office to reject a patent to its blockbuster blood cancer drug Glivec (Imatinib Mesylate).

New Indication Approved for Sutent  -  Feb 12, 2007
Facts and Comparisons,Sutent is also indicated for the treatment of gastrointestinal stromal tumors after disease progression on or intolerance to, imatinib mesylate.

Novartis challenges Patents Act provision  -  Jan 29, 2007
Economic Times,Novartis is hopeful that the hurdles in the patent law in its current form will be removed and that the patent for Imatinib mesylate will be granted,� told

Drug major moves court  -  Jan 29, 2007
Hindu,...application for beta crystalline form of imatinib mesylate, as well as the provisions of the Patents (Amendment) Act 2005 under which it was rejected.

Cardiac Events with Gleevec  -  Feb 13, 2007
eMaxHealth.com,Novartis is notifying healthcare professionals about new precautions for Gleevec (imatinib mesylate). Gleevec is used to treat certain patients with chronic

Amendment to Patents Act defended  -  Feb 22, 2007
Chennai Online,...filed by Novartis challenging the rejection of its application for patenting beta crystalline form of Imatinib Mesylate under section 3(d) of the Act.

Rejecting patents on chemical derivatives is tantamount to "fatwa ...  -  Feb 16, 2007
Hindu,When a batch of petitions filed by Novartis AG against the rejection of its patent application for beta crystalline form of imatinib mesylate came up for

Amendment to Patents Act questioned  -  Feb 16, 2007
Chennai Online,...pharmaceutical major Novartis AG, challenging the rejection of its application for patenting beta crystalline form of Imatinib Mesylate.

The pharmaceutical giant takes the government to court for not ...  -  Feb 16, 2007
Tehelka (subscription),The government rejected the patent application for the cancer drug Imatinib mesylate, marketed under the brand name Gleevec/Glivec in many countries to

Taking TRIPS to India — Novartis, Patent Law, and Access to Medicines  -  Feb 7, 2007
New England Journal of Medicine (subscription),India, to protest the company's efforts to obtain an Indian patent on Gleevec, the company's brand-name version of imatinib mesylate.

Opposition Gains Support Against Novartis Patent Lawsuit In India  -  Feb 15, 2007
Intellectual Property Watch,The Novartis spokesperson told Intellectual Property Watch that this is not a case about access to medicines as the cancer drug, Gleevec (imatinib mesylate)

Cancer drug patent woes mount for Novartis  -  Feb 4, 2007
Daily News & Analysis,Novartis had filed an appeal challenging the rejection of its patent application for leukemia drug Gleevec (imatinib mesylate) by the Madras patent office

Patents and Public Health Crisis Moves Center-Stage  -  Feb 1, 2007
Huffington Post,And, cancer patients who suffer from Chronic Myeloid Leukemia could lose access to Gleevec (imatinib mesylate) because of the patent case filed by Novartis

Novartis questions Indian patent law provisions  -  Jan 30, 2007
Earthtimes.orgNovartis had invented Glivec prior to 1995, but it has filed for a new patent for the chrystalline form of Imatinib mesylate (Glivec's active ingredient),

Researchers develop new strategy for the treatment of CML  -  18 Jan 2007
Hindu,Imatinib mesylate (Gleevec) is a highly effective anti-cancer agent that has revolutionized the course of therapy for patients with CML.

Sutent® Improves Progression-Free Survival Over Interferon in ...  -  18 Jan 2007
Cancer Consultants (press release),...use of Sutent for the treatment of gastrointestinal stromal tumors (GIST) that had progressed after Gleevec® (imatinib mesylate) and for advanced RCC.

Pfizer's Sutent Is Granted Full Marketing Authorization for First ...  -  18 Jan 2007
PharmaLive.com (press release),...and/or metastatic malignant gastrointestinal stromal tumors (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance.

New Treatment Hope For Systemic Sclerosis  -  Jan 3, 2007
Medical News Today (press release),All the specimens were stimulated with TGF' and PDGF and incubated with the inhibitory molecule, imatinib mesylate. Then, applying real-time polymerase

New Treatment Hope For Systemic Sclerosis  -  Dec 29, 2006
Science Daily (press release)Featured in the January 2007 issue of Arthritis & Rheumatism, their experiments indicate the promise of imatinib mesylate to prevent tissue fibrosis and

Gleevec Touted as Possible Treatment for Systemic Sclerosis  -  Dec 28, 2006
MedPage Today,28 -- Gleevec (imatinib mesylate), the cancer drug, may be useful in blocking the pathways involved in systemic sclerosis, according to researchers here.

EU urged to support India in drug-patent battle  -  Jan 17, 2007
EurActiv.com,In January 2006, Novartis's patent application on a cancer drug (imatinib mesylate) was rejected in India on the grounds that it only represented a new form

INNOVIVE Pharmaceuticals Announces Receipt of FDA Orphan Drug ...  -  Jan 8, 2007
PipelineReview.com (press release),1, 2005), INNO-406 is 25 to 55 times more potent than imatinib in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth

Pivotal Submission Data Shows Tasigna(R) Achieved Impressive ...  -  Dec 26, 2006
Medical News Today (press release),Gleevec(R) (imatinib mesylate) tablets are indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic

Nilotinib Effective in Newly Diagnosed Patients with CML  -  Jan 9, 2007
Cancer Consultants (press release),Gleevec® (imatinib mesylate) is a biological agent that binds to and slows or stops the uncontrolled growth of cancer cells with the Philadelphia chromosome

Novartis Urged to Drop India Suit  -  Dec 20, 2006
Red Herring,In January 2006, the Indian patent office for the first time rejected a patent application on Novartis’ cancer drug Imatinib mesylate, which the company

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional